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Benefits of specialisation in the management of pancreatic cancer:
results of a Scottish population-based study
RW Parks*,1, V Bettschart1, S Frame2, DL Stockton2, DH Brewster2 and OJ Garden1
1Department of Clinical and Surgical Sciences, The University of Edinburgh, Royal Inf irmary, 51Little France Crescent, Edinburgh EH16 4SA, UK;
2Information and Statistics Division (NHS Scotland), Trinity Park House, South Trinity Road, Edinburgh EH5 3SQ, UK
Pancreatic cancer is associated with a very poor prognosis; however, in selected patients, resection may improve survival. Several
recent reports have demonstrated that concentration of treatment activity for patients with pancreatic cancer has resulted in
improved outcomes. The aim of this study was to ascertain if there was any evidence of benefit for specialised care of patients with
pancreatic cancer in Scotland. Records of patients diagnosed with pancreatic cancer during the period 1993–1997 were identified.
Three indicators of co-morbidity were calculated for each patient. Operative procedures were classified as resection, other surgery or
biliary stent. Prior to analysis, consultants were assigned as specialist pancreatic surgeons, clinicians with an interest in pancreatic
disease or nonspecialists. Data were analysed with regard to 30-day mortality and survival outcome. The final study population
included 2794 patients. The 30-day mortality following resection was 8%, and hospital or consultant volume did not affect
postoperative mortality. The 30-day mortality rate following palliative surgical operations was 20%, and consultants with higher case
loads or with a specialist pancreatic practice had significantly fewer postoperative deaths (P¼ 0.014 and 0.002, respectively). For
patients undergoing potentially curative or palliative surgery, the adjusted hazard of death was higher in patients with advanced years,
increased co-morbidity, metastatic disease, and was lower for those managed by a specialist (RHR 0.63, 95% CI 0.50–0.78) or by a
clinician with an interest in pancreatic disease (RHR 0.63, 0.48–0.82). The risk of death 3 years after diagnosis of pancreatic cancer is
higher among patients undergoing surgical intervention by nonspecialists. Specialisation and concentration of cancer care has major
implications for the delivery of health services.
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Every year in the UK, around 7000 people are diagnosed with
pancreatic cancer (Office for National Statistics, 2002), and more
than 6500 are recorded as dying from the disease (Quinn et al,
2001). In contrast to many other cancers, there has been little
improvement in survival prospects in recent decades, and
currently, less than 3% of patients remain alive 5 years after
diagnosis (Coleman et al, 1999; Scottish Cancer Intelligence Unit,
2000). Although this dismal prognosis has led to a nihilistic
perspective by some (Gudjonsson, 1995), others have reported 5-
year survival rates following pancreatic resection in excess of 20%
(Yeo et al, 1995). Furthermore, it has recently been suggested that
there may be some scope for improvement in survival figures in
the UK (NHS Executive, 2001; Garden, 2001). This guarded
optimism is based on accumulating evidence that the concentra-
tion of treatment activity among fewer high volume hospitals and/
or surgeons (as a proxy for specialisation) may lead to improved
outcomes for patients with pancreatic cancer (Edge et al, 1993;
Gordon et al, 1995; Lieberman et al, 1995; Neoptolemos et al, 1997;
Gouma et al, 2000; NHS Executive, 2001; Garden, 2001; Rosemurgy
et al, 2001; Teisberg et al, 2001; Halm et al, 2002; Birkmeyer et al,
2002; Bachmann et al, 2003). Many of the studies report reduced
postoperative morbidity and mortality rates, and shorter post-
operative hospital stays following resection of pancreatic cancer,
although few have analysed long-term outcome. Recently, it has
also been shown that increased hospital volume is associated with
a decreased hospital mortality rate for palliative bypass procedures
and for stent insertion as treatment for malignant obstructive
jaundice (Sosa et al, 1998). These phenomena have been related to
the importance of a multidisciplinary approach to both curative
and palliative procedures available in high volume provider
institutions for patients with pancreatic cancer.
The aim of the present study was to investigate whether there is
any evidence of benefit from specialised care of patients with
pancreatic cancer in Scotland, and by inference, whether there is
any scope nationally to improve the outlook of this unfortunate
group of patients.
DATA AND METHODS
The records of residents of Scotland diagnosed with pancreatic
cancer (ICD-9157; ICD-10 C25) during the 5-year period 1993–
1997 were selected from the Scottish Cancer Registry (SCR).
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During this period, the age-standardised incidence rate (world
standard population) per 100 000 was 7.2 in males and 5.3 in
females (Parkin et al, 2002). Equivalent mortality rates for the
same period were 6.7 in males and 4.9 in females (World Health
Organization, 2001). SCR is a population-based registry that covers
the whole of Scotland, with a catchment population of around 5.1
million. Data quality is believed to be high, both in terms of
reliability (Brewster et al, 2002) and completeness of ascertainment
(Brewster et al, 1997). However, in common with many other
countries, a high proportion of pancreatic cancers are not
microscopically verified (Parkin et al, 2002), precise subsite of
origin is often not established or available, and stage of disease at
diagnosis is not collected routinely. Excluded from further analysis
were 178 cases registered on the basis of a death certificate only
(DCO), and 67 nonacinar cell pancreatic cancers (neuroendocrine
tumours (n¼ 27), sarcoma (n¼ 4), cholangiocarcinoma
(n¼ 8), and other tumour types rarely associated with pancreas
as the primary site of origin (n¼ 28)). Although mainly
not microscopically verified, tumours coded as primary
malignant neoplasms, not otherwise specified (NOS) were
included on the basis that they were more likely than not to be
carcinomas.
SCR records were supplemented with information on co-
morbidity, metastatic disease and operative procedures from
hospital discharge (SMR01) records, derived from a permanently
linked database of hospital discharges (including day cases),
cancer registrations, and deaths (Kendrick and Clarke, 1993).
There is evidence that the coding of hospital discharge records in
Scotland is reliable, at least for the main variables, such as primary
operative procedure (Harley and Jones, 1996). Three indicators of
co-morbidity were calculated for each member of the cohort: two
of these – the Charlson score (Charlson et al, 1987) and the
Scottish index (Clinical Outcomes Working Group, 1996) – were
based on selected diagnoses found in any position on SMR01
records within 5 years of the incidence date on the index cancer
registration record. The third co-morbidity index was based on the
number of bed-days of hospitalisation in the 5 years prior to
diagnosis of pancreatic cancer. To avoid confounding due to the
often insidious onset of symptoms and signs of pancreatic cancer,
this index was calculated for the period between 6 months and 5
years prior to diagnosis, and separately for the 6 months
immediately prior to diagnosis.
Operative procedures are coded on SMR01 records according to
OPCS4 (Office of Population Censuses and Surveys, 1990), a widely
used UK classification of surgical operations and procedures.
Based on these codes, inpatient and daycase operative procedures
were classified as resection, other surgery (predominantly
palliative bypass operations), or biliary stent. Prior to analysis,
and based on local knowledge, consultants were assigned to three
categories: specialist pancreatic surgeons, clinicians with an
interest in the pancreas, or nonspecialists. Specialists were defined
as those clinicians who had a recognised multidisciplinary team
with an associated oncologist and pathologist, who contributed to
clinical trials, and who had an established audit system and
regularly reported their results locally and nationally. Clinicians
with an interest in the pancreas were recognised as those who
had a broader interest in upper gastrointestinal conditions but
who were known for co-ordinating the assessment and manage-
ment of patients with pancreatic cancer. Nonspecialists were
defined as those who had a more general clinical practice or were
recognised as having a specific interest in another surgical
subspecialty.
Persons diagnosed with pancreatic cancer during 1993–1997
were assigned to a 1991 census-based Carstairs deprivation
quintile according to their postcode sector of residence at the
time of diagnosis (Morris and Carstairs, 1991). The Carstairs
deprivation score is a small area indicator of socioeconomic status
based on the prevalence measured at the decennial census of four
characteristics: overcrowding, male unemployment, social class,
and car ownership. Deprivation quintile one represents the least
deprived areas of Scotland and deprivation quintile five the most
deprived areas.
Statistical methods
The w2-test was used to assess the statistical significance of
differences in 30-day postoperative mortality rates according to
age-group, year of diagnosis, hospital caseload, consultant case-
load, and consultant specialisation category. Kaplan–Meier
survival analysis was used to obtain estimates of crude survival
at 3 years following diagnosis. The log-rank test was used to test
for equality of survival curves between patients treated by
resection and all other patients. Multivariate Cox’s proportional
hazards models (Collett, 1994) were used to assess separately the
impact of patient-, tumour- and health service-related factors on
survival at 3 years following diagnosis. A final model was based on
the statistically significant factors from the three separate models.
The end point for these analyses was death from any cause.
RESULTS
The final study population included 2794 patients with the
characteristics shown in Table 1. Although the age-standardised
incidence of pancreatic cancer is known to be higher in males than
females, the absolute number of cases is higher in females,
reflecting the age and sex structure of the Scottish population.
Some of the characteristics shown are based on information
derived from linked hospital discharge records, and do not include
outpatient diagnostic or procedural information. Thus, for
example, the number of patients receiving chemotherapy and
radiotherapy may be underestimated.
Table 2 shows the crude 30-day postoperative mortality rates for
patients undergoing surgery or biliary stenting by age-group, year
of diagnosis, hospital workload, workload of main treating
consultant, and consultant specialisation category. Only 4.7% of
the entire cohort of patients underwent potentially curative
surgical resection and the relatively small number of events (10
deaths) mitigate against detecting statistically significant differ-
ences between different categories. The overall 30-day post-
operative mortality following pancreatic resection was 8%, with a
tendency to be lower in the two most recent years of diagnosis
(3%), although this was not statistically significant. There was no
obvious effect of hospital volume on postoperative mortality,
although very few patients were treated in hospitals dealing with
less than 10 cases. Postoperative mortality was generally lower
among patients undergoing potentially curative resection when
treated by consultants with higher caseloads or pancreatic
specialists, but these differences did not achieve statistical
significance (P¼ 0.062 and 0.058, respectively).
The overall 30-day postprocedural mortality following palliative
pancreatic surgery and biliary stenting was 20 and 17%,
respectively. Mortality was significantly higher among the elderly,
and significantly lower in recent years of diagnosis (Table 2).
Significant differences in postoperative mortality rates were
demonstrated in patients undergoing palliative surgical operations
as consultants with higher case loads or with a specialist pancreatic
practice had fewer postoperative deaths (P¼ 0.014 and 0.002,
respectively).
Crude survival at 3 years after diagnosis was 19% in those
patients undergoing resection, but only 2% in other patients
(Po0.001). Table 3 summarises the results of multivariate survival
analysis, presented as adjusted hazard ratios, based on the final
model derived from Cox’s proportional hazard modelling. For the
sake of clarity, only results that achieved (or approached)
statistical significance are shown. For all patients, the adjusted
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hazard of death was higher in patients diagnosed in earlier years,
older patients, males, patients with co-morbidity (based on two out
of four indices), patients with unspecified subsite of tumour,
patients with metastases, patients who did not undergo any form
of surgical procedure or biliary stenting, patients who did not
receive chemotherapy, and patients managed by consultants with a
low caseload. For patients undergoing resection or another
surgical procedure, the adjusted hazard of death was higher in
older patients, patients with co-morbidity (based on the Scottish
index), patients with unspecified subsite of tumour, patients with
unspecified morphology, patients without microscopic verification
of their disease, patients with metastases, patients who did not
undergo biliary stenting, and patients who were not managed by a
specialist pancreatic surgeon or a clinician with an interest in the
field.
Table 1 Characteristics of the study population
Factor No. of cases %
Year of diagnosis
1993 553 19.8
1994 552 19.8
1995 479 17.1
1996 610 21.8
1997 600 21.5
Age groups
0–39 14 0.5
40–49 93 3.3
50–59 312 11.2
60–69 717 25.7
70–79 946 33.9
X80 712 25.5
Sex
Male 1330 47.6
Female 1464 52.4
Carstairs deprivation quintile
(Least deprived) 1 510 18.3
2 600 21.5
3 594 21.3
4 527 18.9
(Most deprived) 5 562 20.1
Unknown 1 0.0
Previous cancer
No 2611 93.5
Yes 183 6.6
Charlson co-morbidity indexa
None 2160 77.3
1–2 conditions 95 3.4
X3 conditions 539 19.3
Scottish co-morbidity indexa
None 1994 71.4
1 condition 516 18.5
X2 conditions 284 10.2
Bed-days co-morbidity index (in 6 months prior to diagnosis)a
None 334 12
1–4 days 284 10.2
5–10 days 453 16.2
X11 days 1723 61.7
Bed-days co-morbidity index (between 6 months and 5 years
prior to diagnosis)a
None 1555 55.7
1–4 days 290 10.4
5–10 days 296 10.6
X11 days 653 23.4
Tumour subsite
Head of pancreas 1263 45.2
Body of pancreas 112 4.0
Tail of pancreas 57 2.0
Other 40 1.4
Unspecified 1322 47.3
Tumour morphology
Neoplasm, not otherwise specified 222 8.0
Carcinoma, not otherwise specified 1523 54.5
Adenocarcinoma, not otherwise specified 902 32.3
Mucin-producing adenocarcinoma 51 1.8
Other 96 3.4
Microscopically verified
No 1616 57.8
Yes 1178 42.2
Metastases within 4 weeks of diagnosisa
No 2023 72.4
Yes 771 27.6
Presence of ascites recordeda
No 2674 95.7
Yes 120 4.3
Surgical resectiona
No 2663 95.3
Yes 131 4.7
Other surgerya
No 2102 75.2
Yes 692 24.8
Biliary stenta
No 2054 73.5
Yes 740 26.5
Chemotherapya
No 2646 94.7
Yes 148 5.3
Radiotherapya
No 2769 99.1
Yes 25 0.9
Caseload of main treating consultanta
Unknown 29 1.0
o5 cases 799 28.6
5–9 cases 612 21.9
10–19 cases 460 16.5
X20 cases 894 32.0
Caseload of hospital of treatmenta
Unknown 29 1.0
1 case 43 1.6
2–9 cases 113 4.1
10–29 cases 132 4.8
X30 cases 2477 89.6
Specialty of main treating consultanta
Specialist 230 8.2
Clinician with an interest in the pancreas 109 3.9
Nonspecialist 2426 86.8
Unknown 29 1.0
Total 2794 100
aInformation derived from linked hospital discharge records does not include
outpatient diagnostic or procedural information.
Table 1 (Continued)
Factor No. of cases %
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DISCUSSION
The results of our study suggest that the risk of death by 3 years
after diagnosis of pancreatic cancer is 37% lower among patients
undergoing surgical intervention who are managed by specialist
pancreatic surgeons or clinicians with an interest in this field. No
advantage of specialisation was seen for the total patient
population, but this probably reflects the fact that surgical
resection offers the best chance of survival (Wade et al, 1994;
Bramhall et al, 1995; Sener et al, 1999), at least for localised disease
(Wade et al, 1995).
The resection rate of 4.7% in this study was low by international
standards (Edge et al, 1993; Baumel et al, 1994; Nakao and Takagi,
1998), but may reflect the small number of patients managed by
specialist pancreatic surgeons or clinicians with an interest in this
field (12.1% of cohort). However, the resection rate did increase
from 3.8% in 1993 to 5.2% in 1997. The development of regional
cancer networks in the United Kingdom in recent years and the
requirement for all patients with cancer to be discussed at
multidisciplinary meetings may result in more patients being
considered for potentially curative surgery. Bachmann et al (2003)
suggested that patients referred to less specialised doctors or
hospitals were less likely to be investigated thoroughly, or to
undergo palliative or potentially curative treatment.
Several studies (Edge et al, 1993; Gordon et al, 1995; Lieberman
et al, 1995; Neoptolemos et al, 1997; Gouma et al, 2000; Garden,
2001; NHS Executive, 2001; Rosemurgy et al, 2001; Teisberg et al,
2001; Birkmeyer et al, 2002; Halm et al, 2002; Bachmann et al,
2003) have suggested that specialisation in this field may yield
better results in terms of postoperative mortality, surgical
complications, and longer term survival, although other studies
have not found this relationship (Wade et al, 1994, 1996), and the
possibility of publication bias must be considered. Some previous
studies are subject to the criticism that in-hospital mortality was
used as an outcome, despite the fact that length of stay may be
lower in patients treated by specialist pancreatic surgeons or
hospitals with higher caseloads (Imperato et al, 1996; Sosa et al,
1998; Gordon et al, 1999; Simunovic et al, 1999; Rosemurgy et al,
2001). Most of the studies used hospital or surgeon caseload as a
proxy for specialisation, and while this may be a reasonable
assumption, others have argued that there is no proof that
repeating a procedure hundreds of times necessarily guarantees
competence (Loefler, 2000). In our own study, when all patients
were considered together, survival was significantly higher for
patients treated by consultants dealing with larger caseloads, but
this factor was not significant in the model concerning only
surgical patients. Although our categorisation of specialist status
might be construed as subjective compared to any definition based
on caseload, it was assigned before analysis.
A major strength of our study is the fact that it is population-
based and not therefore subject to some of the potential
biases inherent in single institution-based studies. However, the
study is based on data collected routinely and not specifically to
fulfil the aims of the study. Although data quality is believed
Table 2 30-day postoperative mortality rates for patients undergoing surgery or biliary stenting by age group, year of diagnosis, hospital workload,
workload of main treating consultant, and specialty of main treating consultant (P-values are shown for statistically significant differences)
Resectiona Other surgerya Biliary stenta
Factor No. of cases No. (%) of deaths No. of cases No. (%) of deaths No. of cases No. (%) of deaths
Age groups P¼ 0.016 P¼ 0.023
0–39 1 0 6 0 5 0
40–49 14 2 (14%) 24 3 (13%) 19 2 (11%)
50–59 30 1 ( 3%) 109 9 ( 8%) 78 7 (9%)
60–69 63 4 ( 6%) 215 36 (17%) 202 22 (11%)
70–79 21 3 (14%) 239 57 (24%) 261 51 (20%)
X80 2 0 99 33 (33%) 175 45 (26%)
Year of diagnosis Po0.001 P¼ 0.001
1993 21 2 (10%) 158 36 (23%) 119 21 (18%)
1994 23 3 (13%) 153 43 (28%) 116 31 (27%)
1995 24 3 (13%) 129 22 (17%) 148 29 (20%)
1996 32 1 (3%) 144 23 (16%) 183 25 (14%)
1997 31 1 (3%) 108 14 (13%) 174 21 (12%)
Caseload of hospital of treatmenta
1 case 0 N/A 0 N/A 0 N/A
2–9 cases 0 N/A 10 2 (20%) 1 0
10–29 cases 0 N/A 33 12 (36%) 18 4 (22%)
X30 cases 131 10 (8%) 649 124 (19%) 721 123 (17%)
Caseload of main treating consultanta P¼ 0.014
1 case 7 1 (14%) 102 21 (21%) 88 18 (21%)
2–4 cases 11 3 (27%) 177 37 (21%) 112 24 (21%)
5–9 cases 18 1 (6%) 176 47 (27%) 108 16 (15%)
X10 cases 95 5 (5%) 237 33 (14%) 432 69 (16%)
Specialty of main treating consultanta P¼ 0.002
Specialist 51 1 (2%) 86 6 (7%) 120 13 (11%)
Clinician with an interest in the pancreas 32 2 (6%) 50 7 (14%) 33 7 (21%)
Nonspecialist 48 7 (15%) 556 125 (23%) 587 107 (18%)
Total 131 10 (8%) 692 138 (20%) 740 127 (17%)
aInformation derived from linked hospital discharge records does not include outpatient diagnostic or procedural information. Note that patients can appear in more than one of
the treatment groups. N/A: not applicable.
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Table 3 Adjusteda hazard ratios of death (and 95% confidence intervals) within 3 years of diagnosis
All patients Surgical patientsb
Factor HR (95% CI) P-value HR (95% CI) P-value
Year of diagnosis No statistically significant differences
1993 1.00
1994 0.98 (0.87, 1.11) 0.779
1995 0.94 (0.83, 1.06) 0.309
1996 0.81 (0.72, 0.92) 0.001
1997 0.88 (0.78, 1.00) 0.043
Age groups
0–49 1.00 1.00
50–59 0.95 (0.75, 1.19) 0.648 1.00 (0.69, 1.46) 0.982
60–69 1.14 (0.92, 1.41) 0.241 1.26 (0.88, 1.78) 0.205
70–79 1.14 (0.92, 1.41) 0.245 1.41 (0.99, 2.02) 0.06
X80 1.41 (1.12, 1.76) 0.003 1.83 (1.22, 2.75) 0.003
Sex No statistically significant differences
Male 1.00
Female 0.92 (0.85, 1.00) 0.042
Scottish co-morbidity indexb
None 1.00 1.00
1 condition 1.24 (1.12, 1.37) o0.001 1.09 (0.91, 1.32) 0.351
X2 conditions 1.25 (1.09, 1.42) 0.001 1.51 (1.12, 2.05) 0.007
Bed-days co-morbidity index (in 6 months prior to diagnosis)b No statistically significant differences
None 1.00
1–4 days 1.11 (0.94, 1.30) 0.226
5–10 days 1.20 (1.03, 1.39) 0.017
X11 days 1.33 (1.17, 1.50) o0.001
Tumour subsite
Head of pancreas 1.00 1.00
Body of pancreas 1.01 (0.83, 1.24) 0.918 1.19 (0.78, 1.83) 0.425
Tail of pancreas 0.97 (0.74, 1.28) 0.849 1.18 (0.55, 2.54) 0.665
Other 1.12 (0.81, 1.55) 0.499 0.86 (0.48, 1.52) 0.595
Unspecified 1.20 (1.10, 1.30) o0.001 1.34 (1.15, 1.56) o0.001
Tumour morphology No statistically significant differences
Neoplasm, not otherwise specified 1.00
Carcinoma, not otherwise specified 0.74 (0.51, 1.07) 0.107
Adenocarcinoma, not otherwise specified 0.62 (0.42, 0.93) 0.022
Mucin-producing adenocarcinoma 0.48 (0.27, 0.85) 0.011
Other 0.39 (0.23, 0.66) o0.001
Microscopically verified No statistically significant differences
No 1.00
Yes 0.68 (0.55, 0.85) 0.001
Metastases within 4 weeks of diagnosisb
No 1.00 1.00
Yes 1.92 (1.76, 2.10) o0.001 1.93 (1.60, 2.33) o0.001
Surgical resectionb Not applicable
No 1.00
Yes 0.38 (0.31, 0.46) o0.001
Other surgeryb Not applicable
No 1.00
Yes 0.74 (0.67, 0.81) o0.001
Biliary stentb
No 1.00 1.00
Yes 0.72 (0.65, 0.79) o0.001 0.70 (0.57, 0.85) o0.001
Chemotherapyb No statistically significant differences
No 1.00
Yes 0.59 (0.50, 0.71) o0.001
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to be reasonable (Harley and Jones, 1996; Brewster et al, 1997,
2002), it is unlikely to be as high nor as detailed as if the data
had been collected prospectively. We were obliged to accept the
reality that, in this and many other countries (Parkin et al, 2002),
a high proportion of pancreatic cancers have no information
on precise subsite of origin, and are not verified by microscopy.
However, given the very poor survival prospects for patients
registered with pancreatic cancer in Scotland (Scottish Cancer
Intelligence Unit, 2000), it seems unlikely that the cancer registry
includes many clinically diagnosed cases of pancreatic cancer that
are actually cases of benign pancreatic disease. Restriction of our
analyses to microscopically verified cases only would, in our
opinion, have introduced a substantial risk of bias.
Given the importance of tumour stage as a prognostic variable
(Wade et al, 1995), the absence of this variable is an acknowledged
limitation, although its importance as a discriminating variable
may be less among the cohort of patients undergoing surgery.
Although we cannot exclude residual confounding as an
explanation for our results, it seems counter-intuitive that
surgical patients with more favourable subsites of origin, more
limited disease, and requiring less technically demanding proce-
dures would be referred selectively to specialist surgeons. In
relation to the variables available for our study, it is likely that
some misclassification exists, although if this is random with
respect to specialist status, it will have attenuated rather than
exaggerated the differences in outcome by this factor. The
prognostic impact of other factors, such as age, presence of
metastases at diagnosis and co-morbidity, is plausible and
expected. Although microscopic verification of diagnosis appears
to have no statistically significant effect on the survival of all
patients combined, it is associated with higher survival in surgical
patients, presumably because resection is always likely to result in
tissue diagnosis.
It is interesting to note that, although almost 90% of patients
were treated in high volume hospitals, slightly less than half were
managed by consultants treating 10 or more cases (Table 1). Thus,
any shift in referral patterns towards higher volume surgeons may
not have a substantial impact on patient travel times.
When considering the policy implications of the present study
and related studies, it is important to acknowledge that not
everyone is convinced of the merits of specialisation which does
have some theoretical disadvantages (Loefler, 2000). However, the
body of evidence is now such that we would suggest that the onus
is on sceptics to provide evidence that surgical specialisation offers
no advantages, or at least that the disadvantages outweigh the
benefits. From a pragmatic point of view, we believe that the
individual faced with a diagnosis of pancreatic cancer would wish
to be managed by a multidisciplinary team including a surgeon
with specific training in this area and an annual caseload above a
certain minimum threshold.
In conclusion, we have shown that surgically treated patients
with pancreatic cancer are likely to fare better if they are managed
by specialist pancreatic surgeons, or clinicians with an interest in
this field. Although we cannot exclude entirely the possibility of
bias or confounding, our results add to a growing body of evidence
supporting specialisation of surgery for pancreatic malignancy.
This has major implications for the delivery of cancer services in
Scotland and the rest of the UK.
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